Nemaura Launches BEATdiabetes Program and proBEAT Non-invasive CGM in the US
Nemaura announced the US launch of its BEATdiabetes program and proBEAT non-invasive CGM. Recall, Nemaura’s non-invasive sugarBEAT CGM was originally filed under the wellness category (and launched in the US as proBEAT) for people with T2DM and prediabetes as part of the BEATdiabetes platform. A PMA has been filed for sugarBEAT and Nemaura anticipates FDA approval and a US launch by YE ’21. Below, FENIX provides brief insight on the BEATdiabetes launch in the context of Nemaura as an acquisition target.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.